Based on a talk delivered in the Symposium 'Uses and challenges for human pharmacology studies to understand CNS Diseases' convened at the British Pharmacological Society Meeting in London, 16 December 2016. This review advances the case that bidirectional, cross-species translation of findings from experimental animals to and from humans is an important strategy for drug discovery. Animal models of mental disorders require appropriate behavioural or cognitive outcome variables that can be generalized cross-species. One example is the treatment of impulsive behaviour in attention deficit hyperactivity disorder (ADHD) with stimulant drugs. Performance on the stop signal reaction task as an index of impulsivity is improved both in healthy human volunteers and in patients with adult ADHD by stimulant drugs and also by the selective noradrenaline reuptake blocker atomoxetine. Functional neuroimaging evidence suggests a modulation of circuitry including the inferior prefrontal cortex by this drug. Parallel work in rats had shown that atomoxetine improves stop signal performance by affecting possibly homologous regions of the rodent prefrontal cortex. This parallel effect of atomoxetine in rodents and humans could potentially be exploited in other disorders in which impulsivity plays a role, such as stimulant abuse and Parkinson's disease. A contrasting relative lack of involvement of 5-HT mechanisms in the stop signal reaction time task will also be described. Research in humans and experimental animals that demonstrate effects of serotoninergic agents such as the selective serotonin (5-HT) reuptake inhibitor citalopram on probabilistic learning and reversal (upon which atomoxetine has little effect) will also be reviewed, possibly relevant to the treatment of clinical depression, Finally, other promising examples of parallel studies of behavioural effects of CNS-active drugs in animals and humans will also be described.
Introduction
Cognition can be defined as the way in which representations in the brain are used to produce thinking or behaviour. Cognition subsumes perception, attention, working, episodic and semantic memory, associative learning, language and executive control processes that co-ordinate these functions to produce decision-making, planning and the regulation of behaviour. Cognition also interacts with motivational and emotional processes and may include social functions. Cognitive processes are mediated by neural networks in mammals that include regions of the neocortex, such as the temporal, parietal and frontal lobes, which interact with the sub-cortical brain. The building blocks of these processes can be studied in experimental animals and used for drug discovery. Cognition is not unitary and probably depends on a number of functions mediated by distinct neural networks that require assessment by a cognitive test battery approach. Classically, the 'battery' approach in humans has used the Wechsler Adult IQ Scale (which nevertheless extracts a 'general' measure of IQ) and more recently the MATRICS battery for schizophrenia (http://www.matricsinc.org/ MCCB.htm). Recognizing the parallels with experimental animals, we invented the largely non-verbal CANTAB battery (http://www.cambridgecognition.com/academic/ cantabsuite/battery), which utilizes computerized tests that can be given to both humans, including clinical patients, and experimental animals (non-human primates or with suitably modified tests, rodents).
The great expense of Phase 3 trials and lack of success of developing effective new compounds in clinical neuroscience has questioned the utility of animal models of cognitive human disorders. However, the crucial validation test of back-translation of such models has often not been facilitated by multi-centre clinical trials using heterogeneous patient groups based on imperfect categorical diagnostic classifications and insensitive outcome measures based on clinical scales, sometimes of compounds that fail to engage with the target mechanism and have adverse side-effects. This article suggests a way of improving this situation, with a number of examples in which animal and human studies have illustrated the principle of bidirectional translatability. In this strategy, effects of drug with known safety profiles are tested in proof of principle studies in healthy and human volunteers, and parallel studies in experimental animals help to define the neural and neurochemical mechanisms underlying the drug's actions. This approach may also enable the repurposing of compounds, as well as validating new approaches to drug discovery. It requires a re-appraisal of what we can expect from 'animal models'. Disease models are currently possible for neurological disorders but not readily for neuropsychiatric disorders, except to simulate relevant disruptions in particular neural systems or forms of cognitive function that can be ameliorated by drug treatment. However, this form of model, which focuses on symptoms rather than aetiology, can nevertheless be informative. We illustrate the approach by reviewing inter-related studies examining aspects of executive function, relevant to a number of neuropsychiatric and neurological disorders.
Executive functions are control processes that serve to optimize performance by co-ordinating different aspects of cognitive functioning. This optimization may, for example, lead to the efficient collection of reinforcers such as food or money and the avoidance of countervailing penalties or costs. Executive functions are frequently associated with the functioning of different sectors of the prefrontal cortex (PFC) interacting with diverse neural networks. They are impaired in many neuropsychiatric disorders, including schizophrenia, depression, addiction, attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Executive functions include not only the control of working memory but also cognitive flexibility in the face of changing environmental circumstances (attentional set-shifting and reversal learning) and 'cognitive' or inhibitory response control', disruptions of which can lead to impulsive and compulsive behaviour (Friedman et al., 2006) .
There are several equivalent tests of impulsivity in rodents and humans (Dalley and Robbins, 2016) . These tests include a sophisticated form of the so-called Go/NoGo test, the stop signal reaction time task (SSRTT) (Eagle and Robbins, 2003; Logan et al., 2014; Figure 1A) , which is often used to measure motor impulsivity in ADHD (Solanto et al., 2001) . This test estimates how long it takes to cancel an initiated response. A stop signal is presented on about 20% of trials to indicate that responses should be inhibited or cancelled on that trial. This stop signal is interpolated at varying durations (of the order of ms) after the onset of a Go cue. At longer delays, it is thus correspondingly more difficult to cancel the response, as reflected by increased stop errors and longer SSRTs, which can be taken as a measure of impulsiveness. The SSRTT assumes there is a 'race' between independent 'go' and 'stop' processes; whichever 'wins' determines the outcome of the trial (Logan et al., 2014) .
Pharmacological remediation of ADHD
ADHD already provides an excellent example of pharmacological cognitive remediation, especially of its associated impairments in executive functioning. This disorder, which includes symptoms of attentional deficits, impulsive behaviour and hyperactivity, responds remarkably well to psychomotor stimulant drugs such as methylphenidate (Ritalin R ) and amphetamine, with amongst the highest effect sizes in clinical trials in psychiatry (Biederman et al., 2004) . The modes of action of amphetamine and methylphenidate at the molecular level are quite well understood and include, for example, inhibition of the dopamine (DAT) and noradrenaline (NET) transporters that effect reuptake of the released neurotransmitter from the synapse into the pre-synaptic terminal. However, which of these neurotransmitters and which of their neural loci of action is ultimately responsible for ameliorating different symptoms in ADHD is not clear (Del Campo et al., 2011) . One compound that can cast light on these issues is the atypical stimulant atomoxetine (Strattera R ), which is a more selective blocker of NA re-uptake and has proven efficacy in ADHD although not at the same level of effectiveness as Ritalin in the short term (Biederman et al., 2004) [although the efficacy of atomoxetine in juvenile ADHD may increase with longer term treatment (Clemow and Bushe, 2015) ]. Atomoxetine does also increase levels of dopamine in the PFC, as a consequence of how dopamine is regulated by the NA transporter in that region (Bymaster et al., 2002) , which essentially means that it differs from such drugs as methylphenidate and amphetamine, primarily by its lack of action on subcortical dopaminergic systems, which are associated with drug abuse. Consequently, comparison of the effects of such drugs in ADHD using objective laboratory tests of executive function may have utility. Consequently, it is revealing that both methylphenidate and atomoxetine have similar remediating effects on SSRTT performance in adult ADHD, whereas actions on working memory are superior under methylphenidate (Chamberlain et al., 2007a; Del Campo et al., 2011) . This implies that methylphenidate positively affects a broader range of executive functions than atomoxetine, although the latter drug is effective against impulsivity. This in turn suggests that it is the effects on the NA system that may be more relevant for understanding the anti-impulsive effects of atomoxetine.
We have subsequently tested this hypothesis in a number of ways that include parallel studies in healthy human volunteers and rodents.
Cross-species studies of laboratory studies of effects of atomoxetine on SSRT performance
The key study (Chamberlain et al., 2006) compared effects of atomoxetine with those of placebo and a selective 5-HT (serotonin) reuptake inhibitor (SSRI) citalopram on a test battery including the SSRT task in healthy human volunteers. Single doses of atomoxetine (60 mg) and citalopram (30 mg) were used that corresponded to optimal doses used clinically. Atomoxetine significantly improved performance, reducing the SSRT whereas the SSRI had no effect, compared with placebo ( Figure 1 ). It seemed unlikely that the effects of atomoxetine could be attributed simply to improved alertness as the drug did not improve sustained attention on Figure 1 (A) On the human stop signal task, subjects respond rapidly to left-or right-facing arrows on screen with corresponding motor responses and are required to inhibit responses when an auditory stop signal 'beep' sounds. During the task, the time between stimulus onset and occurrence of the stop signal is varied by means of a tracking algorithm, which permits calculation of the SSRT, an estimate of the time taken to internally suppress pre-potent motor responses. The average response time for Go trials is also recorded. Significant effects of 60 mg atomoxetine (ATO) are indicated for the SSRT measure relative to placebo (PLA) control and 30 mg of the SSRI citalopram (CIT). (B) On the human probabilistic learning and reversal task, volunteers are required to make a forced choice between two stimuli (one red, one green) on each trial. The 'correct' stimulus (always the first stimulus touched) receives an 80:20 ratio of positive : negative feedback, and the opposite ratio is provided for the 'incorrect' stimulus. Feedback is provided in the form of the words 'CORRECT' or 'INCORRECT' appearing on screen after each choice. Learning of this stimulus-reward association on the basis of this feedback is assessed by the number of errors made before reaching criterion, defined as eight consecutive correct responses to the maximally rewarded stimulus. After the first 40 trials (stage 1), the contingencies reverse for the subsequent 40 trials (stage 2) (i.e. if 'red' was previously correct, then 'green' becomes correct). The ability to acquire the new stimulus-reward association is again assessed by the number of errors made before reaching criterion. The detrimental effect of misleading negative feedback on learning is assessed by means of an overall 'negative feedback sensitivity' score. This is defined as the overall likelihood that the volunteer inappropriately switched to choose the incorrect stimulus after misleadingly being informed by the spurious negative feedback that his or her correct response on the previous trial was incorrect. CIT (30 mg) significantly increased the sensitivity to negative feedback compared with ATO and control treatments. Overall errors were also increased at each stage of the task by CIT (not shown). Data from Chamberlain et al. (2006) . a test of rapid visual information processing. Although a later study, using a much larger group of volunteers did detect a positive effect also on this task (Crockett et al., 2010) . A further question, therefore, was the site of action of the drug in the brain. A follow-up study examined the effects of atomoxetine on SSRTT performance in healthy volunteers undergoing functional MRI (fMRI) (Chamberlain et al., 2009) . The neural network mediating the task had already been quite well characterized, to include the right inferior frontal cortex and anterior cingulate, as well as the premotor and supplementary motor cortex and basal ganglia (Aron and Poldrack, 2006) . In the study of Chamberlain et al. (2009) , atomoxetine increased the blood oxygenation leveldependent response specifically in the region of the right inferior frontal cortex. Moreover, these effects were dosedependent. Although only one dose of the drug had been administered (as is usual in human studies for logistic and ethical reasons), it was possible to infer a dose-dependent effect by utilizing the individual differences on plasma levels of the drug. These correlated significantly with the effects of the drug on the activation in the right inferior frontal cortex on successful (but not failed) SSRT trials. The implication of the right inferior cortex is interesting in the context of a large study of the neural network subserving SSRT performance in 2000 adolescents in which it was also shown that alleles of a polymorphism of the NA transporter (SLC6A2; rs36024, intron 4) were associated with activation of this region (Whelan et al., 2012) .
Further studies of the efficacy of atomoxetine in the SSRT task have been made in the context of studies treating some of the executive impairments in Parkinson's disease with atomoxetine. In fact, atomoxetine also improved SSRT performance in individuals with Parkinson's disease, depending on such factors as severity of disease and degree of white matter loss connecting the cortex and the striatum. Functional connectivity analyses indicated that atomoxetine enhanced connectivity between key structures mediating SSRT such as the right inferior frontal gyrus and the anterior cingulate nucleus (Borchert et al., 2016) whilst enhancing fronto-striatal interactions in Parkinson's disease (Ye et al., 2015) .
The beneficial effects of atomoxetine on SSRT performance have been paralleled by studies in rodents. Using the SSRT paradigm devised by Eagle and Robbins (2003) , Robinson et al. (2008) showed that the drug produced dose-dependent improvements in SSRT performance whilst not affecting parameters of performance such as the Go reaction time in rats. These effects were extended by Bari et al. (2009) who showed, congruent with the human findings with the SSRI, that acute citalopram failed to affect specifically SSRT over a range of doses. Furthermore, a selective dopamine reuptake blocker GB12909 actually impaired SSRT performance, highlighting the possibility that enhancing subcortical dopamine levels could produce impulsive behaviour, and incidentally indicating that the effects of methylphenidate on subcortical dopamine may produce counterproductive effects on impulsive behaviour. In fact, D 1 and D 2 striatal dopamine receptors may produce opposing effects on SSRT performance .
Note that the approach advocated may yield apparent anomalies in back-translation, which question the overall approach -but which might also lead to re-appraisal of the efficacy of some compounds. Thus, the α 2 adrenoceptor agonist guanfacine is sometimes used in the treatment of ADHD when first-line treatments fail -whereas this drug only appears to impair SSRT performance in rodents (Bari et al., 2009 (Bari et al., , 2011 whilst having no beneficial effect in adult humans at the doses tested (Müller et al., 2005) . However, guanfacine is not licensed in Europe for the treatment of adult ADHD. Moreover, a different animal model (using the five-choice serial reaction time task) showed that, whilst guanfacine did have anti-impulsivity actions, these only occurred at doses with apparent sedative actions (Fernando et al., 2012) . It is quite possible that rodent models of ADHD that attempt to simulate the diagnostic profile of inattention, hyperactivity and impulsivity might be useful in conjunction with tasks such as the SSRT to provide a more accurate prediction for drug discovery [e.g. the spontaneously hypertensive rat (but see Van der Kooij and Glennon, 2007 for a critique) or the NK-1 receptor knockout (k.o.) mouse (Yan et al., 2011) ]. The beneficial effect of atomoxetine on SSRT has in fact recently been confirmed in a mouse version of the SSRT task (Humby et al., 2013) , and so, it could readily be employed in the NK-1 k.o. model.
However, in the absence of definitive knowledge about the aetiology of ADHD, findings in such models have to be interpreted with caution in the context of drug discovery. Thus, for example, although the NK-1 k.o. mouse showed reductions in locomotor activity in response to all of the major ADHD medications, its impulsive behaviour and inattention were not remediated by d-amphetamine (Yan et al., 2011) . Equally, the strategy we have advanced could be used to assess possible new medications for ADHD that address the clinical need for agents lacking drug abuse potential, such as the novel catecholamine reuptake inhibitors dasotraline and centenafadine. We have already shown parallel efficacy on the SSRT task in rats (Eagle et al., 2007) , healthy volunteers (Chamberlain et al., 2006) and adults with ADHD (Turner et al., 2004a) for the atypical stimulant modafinil, which has little, if any, abuse liability. Bari et al. (2011) further explored the central substrates of the effects of atomoxetine on SSRTT performance in rats by using intra-cerebral infusion methodology. It had already been shown in this species that there were critical regions of the PFC that appeared necessary for optimal SSRTT performance . Excitotoxic lesions of either the dorsal cingulate/prelimbic region or the lateral orbitofrontal cortex significantly prolonged SSRT, with the latter manipulation being more potent. Both of these regions project to the dorsomedial striatum, and previous studies had already shown the importance of this region and the subthalamic nucleus for optimal SSRT performance. Bari et al. (2011) showed that atomoxetine produced improvements in SSRT when infused into either the dorsal PFC or lateral orbitofrontal region, the latter being more effective. The rodent lateral orbitofrontal cortex is a plausible, though controversial, homologue of the human inferior frontal cortex. Nevertheless, the Bari et al. 
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also enabled a better pharmacological characterization of the effects of atomoxetine in terms of its actions on dopamine-or NA-dependent mechanisms. Specifically, Bari et al. (2011) found that infusion of the mixed dopamine-receptor antagonist α-flupenthixol into the dorsal PFC had no effect on SSRT performance whereas the α 2 adrenoceptor agonist guanfacine had opposite effects to those of atomoxetine, presumably via inhibitory catecholamine autoreceptors. Therefore, it appears that the actions of atomoxetine on cortical NA are indeed implicated in its actions.
Using similar methodology, via its implication in treating impulsivity, we have also been able to test the possible efficacy of atomoxetine in remediating cognitive functioning in Parkinson's disease (Kehagia et al., 2014) and also in drug addiction (Economidou et al., 2011; Passimonti et al., 2017 ) -thus exploring the potential for possible repurposing of the drug beyond its current application in ADHD.
Laboratory studies of SSRIs in the context of depression and OCD
Although an acute dose of the SSRI citalopram had no significant effects on SSRT in human volunteers in the study of Chamberlain et al. (2006) , it did exert a significant impairment in a test of probabilistic and reversal learning ( Figure 1B ). This effect is significant in terms of human depression, as previous evidence had shown that patients with depression respond in a characteristic manner in this task (Murphy et al., 2003) . The test is essentially one of reinforcement learning in which participants chose one of two stimuli appearing in different locations on a touchsensitive screen. One of the stimuli was correct for 80% of trials, and the other 20%, meaning that positive ('rewarding') and negative ('punishing') feedback was dispensed on those trials according to that schedule. Optimal learning occurs when the subjects devote all of their responses to the 80% option, a well-established 'maximization' strategy in animal studies. This probabilistic schedule was also relevant to the second phase of the test in which the reinforcement contingencies were reversed, as it clearly requires the participants to sample more trials and therefore to obtain more evidence to determine whether a change in reinforcement contingencies has occurred, assumed to be necessary for achieving reversal learning. Reversal learning hypothetically also requires executive processes of response inhibition to prevent the perseverative responding that may underpin maladaptive compulsive behaviour. It is thus especially relevant to such psychiatric disorders as OCD (Chamberlain et al., 2008) and also schizophrenia (Leeson et al., 2009) , and 5-HT (serotonin) has been implicated in both probabilistic learning and reversal, both in humans and non-human primates (Murphy et al., 2002; Clarke et al., 2004) .
Previous work had shown that patients with major depressive disorder often respond maladaptively when responding to the spurious 'punishment' feedback on 20% of successful choices, by significantly switching their response on the next trial to the other (incorrect) stimulus (Murphy et al., 2003) . This tendency may relate to a hypothetically exaggerated sensitivity to negative events shown by patients with affective disorders. Thus, this test paradigm provides a way of measuring this sensitivity in both patients and animals, as a putative behavioural model of some aspects of depression.
Animal versions of the probabilistic reversal paradigm are easy to implement. In the case of a non-human primate such as the marmoset, this can readily be implemented using the same computerized touch-screen technology. For the rat or mouse, probabilistic learning and several serial reversals can be implemented using a two-lever operant chamber. Bari et al. (2010) implemented the paradigm for rats using a range of 5-HT treatments that far exceeded those which could be given to human participants, including doseresponse determinations for acutely administered citalopram, sub-chronic citalopram treatment and profound forebrain 5-HT depletion, effected by treatment with the 5-HT neurotoxin 5,7 dihydroxytryptamine administered intra-ventricularly. These treatments produced largely predictable effects on probabilistic reversal performance. Notably, the low acute dose (1 mg·kg À1 ) of citalopram produced the same tendency to lose-shift (i.e. sensitivity to negative feedback) inappropriately as was found in the human study (Chamberlain et al., 2006) -reducing the number of successful reversals. However, a higher acute dose (10 mg·kg À1 ) had exactly the opposite effect, to reduce lose-shift behaviour and to improve serial reversal learning (Table 1) . We assume that the lower dose was affecting inhibitory 5-HT autoreceptors, probably at the level of the cell bodies of the raphé nuclei, whereas a higher dose was working preferentially at 5-HT post-synaptic receptors. This analysis assumes that in fact, the acute dose of citalopram was operating primarily at inhibitory autoreceptors in the Chamberlain et al. (2006) study, thereby producing diminished 5-HT function and incidentally resembling the behaviour of patients with depression. Moreover, in the rodent study, sub-chronically administered citalopram significantly improved performance by increasing the number of successful reversals, thereby presumably simulating its clinical effect, which is assumed to depend on enhancing 5-HT function. The neural site of action of these manipulations of 5-HT has also been addressed by a study in a non-human primate, the marmoset monkey. Utilizing a very similar test paradigm for the probabilistic learning/reversal task as has been employed for the human studies, Rygula et al. (2014) have effected local depletions of 5-HT bilaterally in the amygdala and orbitofrontal cortex, two key structures implicated in processing aversive feedback. They found qualitatively similar behavioural effects at both sites. 5-HT depletion in the amygdala impaired response choice on a probabilistic visual discrimination task by increasing the effectiveness of misleading, or false, punishment, as well as reward. This more general loss of reinforcer efficacy was confirmed by modelling, based on reinforcement learning theory.
Atomoxetine had no effect on probabilistic learning and reversal in humans (Chamberlain et al., 2006) , and so these effects of the SSRI were pharmacologically selective to some extent, as had been the case for atomoxetine's effect on SSRT. Together, these studies indicate the degree of informative cross-species translation that is feasible in human and rodent studies and which aids the understanding of the mechanisms by which the drugs work clinically.
Future applications of the translational strategy
Both the SSRTT and probabilistic learning and reversal paradigms are potentially useful in several other applications addressing clinical unmet needs. Probabilistic learning is relevant for translating discoveries about the role of dopaminergic neurons in mediating prediction errors of reward in reinforcement learning in experimental animals (Schultz, 2015) , the possible role of such prediction errors in delusions (Corlett et al., 2007; Murray et al., 2008) and the therapeutic effects of dopamine D 2 receptor antagonist drugs in alleviating positive symptoms in psychosis (Seeman, 2010) . Thus, Eisenegger et al. (2014) used a variant of the probabilistic learning task (reward : punishment ratio for the two choices, 75:25%) to re-examine effects of an effective (800 mg) dose of the D 2/3 receptor antagonist sulpiride on reinforcement learning in healthy human volunteers. Somewhat surprisingly, in contrast to predictions of prevailing models emphasizing dopamine's pivotal role in learning via prediction errors (Pessiglione et al., 2006) , it was found that sulpiride did not disrupt initial learning, but rather induced impairments in choice performance in the later stage of the task. Thus, dopamine D 2 receptor antagonism appeared to have induced behavioural impairments only after learning had occurred. The disruption was selective for stimuli indicating reward, whilst loss avoidance performance was unaffected. Effects were significantly pronounced in volunteers with higher serum levels of the drug and in those with a genetically determined lower density of striatal dopamine D 2 receptors. The findings challenge current reward prediction error models of reinforcement learning by suggesting that classical animal models emphasizing a role of postsynaptic dopamine D 2 receptors in motivational aspects of reinforcement learning may well apply to humans as well. The findings are in fact compatible with other results that indicate the prediction errors to be mediated by phasic bursts of dopamine cell firing that may be especially sensitive to D 1 receptor agents, perhaps in combination with NMDA receptor actions (Dreyer et al., 2010) . This hypothesis remains to be tested further in both experimental animal and humans, partly because of the lack of availability of a suitable drug for human studies of this nature in healthy volunteers.
A second example of 'back-translation' can be found using measures of another prominent component of executive functioning, cognitive flexibility, which can also be investigated in parallel in human and animal studies. Attentional set-shifting tests sensitive to damage to the PFC require the formation and shifting of attentional 'sets' and the capacity to withhold a pre-potent response to one aspect of a stimulus in order to respond to another (Keeler and Robbins, 2011) . Such tests have proven highly translational in a range of experimental animals, including mice, rats, marmoset monkeys, rhesus monkeys and humans, in ways that reflect neural homologies; thus, attentional set-shifting implicates the lateral PFC in primates, including humans (but the medial PFC in rodents), on the basis of both lesion and neuroimaging studies, whereas reversal learning appears to implicate the orbitofrontal cortex from studies of humans, marmosets, rats and mice (see review in Keeler and Robbins, 2011) .
The attentional set-shifting task uses compound visual stimuli, which vary in at least two perceptual dimensions such as purple visual shapes with superimposed white lines for primates (Dias et al., 1996) , or alternatively, for rodents, distinct textures and odour stimuli in different modalities (Birrell and Brown, 2000) . Humans, non-human primates or rodents (rats or mice) are trained to attend to one dimension on the basis of positive feedback or reinforcement and to ignore the other by a number of distinct training stages that serve to focus the subject's attention onto particular features of the stimuli and to ignore the others, with the result that they have a prepotent tendency to respond to the trained dimension (e.g. shapes). Finally, an extra-dimensional shift (ed-shift) is programmed with exemplars, for which the previously irrelevant dimension (e.g. 'lines') is reinforced. This latter stage is analogous to the category shift on the Wisconsin Card Sort Test. In the rodent version (available for mice as well as rats), the test is implemented using olfactory and sand texture cues in a 'digging for food' test paradigm (Birrell and Brown, 2000) . 
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Performance across the various stages is qualitatively comparable with that seen in primates; the ed-shift (and also reversal) stages are the most sensitive stages to drug effects, performance at other stages usually being employed as internal controls for more trivial behavioural explanations of the effects. This paradigm has had several applications in neuropsychiatry, including OCD (Chamberlain et al., 2007b) and schizophrenia, potentially addressing clinical unmet need. In the latter case, the attentional set-shifting paradigm has been shown to be sensitive to cognitive enhancing effects of modafinil in patients with schizophrenia in a double-blind, placebo-controlled, proof of principle study: performance under modafinil effectively normalized performance in high-functioning patients with schizophrenia (Turner et al., 2004b) . This study apparently stimulated an impressive, though rare, case of 'back-translation' using the rodent version of this paradigm. Thus, a common 'perturbation' of modelling schizophrenia was employed in rats -sub-chronic treatment with the NMDA receptor antagonist phencyclidine, which impairs relatively selectively the ed-shifing stage of the procedure. Remarkably, this deficit was rescued by treatment of the rats with acute modafinil, thus mimicking the human finding (Goetghebeur and Dias, 2009) .
This demonstration indicates the strategy for the future we have advocated above; to study effects of drugs in human volunteers on cognitive function; and if promising results are found, to follow-up with animal studies designed to simulate the human drug effects so that underlying mechanisms can be studied further, possibly including the development of improved compounds. The rodent attention-set shifting paradigm (originally developed from a version in non-human primates) has been used in several drug discovery programmes associated with detecting drugs of possible utility in the treatment of cognitive deficits in schizophrenia (Brown and Tait, 2016) . Of course, the approach can also be deployed in a more conventional fashion -given the validation of the behavioural methodology, this can be used in preclinical drug screening to predict drug effects in humans in Phase 1 or 2 studies, and if feasible, to include comparable cross-species measures as part of Phase 3 studies to test by back-translation whether the concept had utility. An example is the effect of an mGlu 2/3 receptor-positive allosteric modulator, which was shown to improve both reversal learning and ed-shifting in rats subjected to early treatment with the mitotic neurotoxin methylazoxymethanol acetate at developmental stage E17 (Gastambide et al., 2011) . Of course, a necessary validation of this effect would be to test the drug in patients using the same paradigm, but for various reasons, this was never attempted.
Conclusion
In this brief review, the case for more effective cross-species translation of findings has been made using a bidirectional translational approach both to improve the investigation of underlying mechanisms of drug effects on cognition and to validate preclinical findings in drug discovery. The approach rests on the need to develop better measures of cognition cross-species, so that more informative comparisons can be made between studies of humans and experimental animals, also employing advances in neuroscience to add a neural dimension to attempts at producing new animal models of specific symptoms of psychiatric disorders, such as impulsivity and impaired executive function.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
